<i>In Silico</i> Fragment-Based Drug Design and Molecular Docking of Tranilast Analogues as Potential Inhibitors of Transforming Growth Factor- β Receptor Type 1

<i>In Silico</i> Fragment-Based Drug Design and Molecular Docking of Tranilast Analogues as Potential Inhibitors of Transforming Growth Factor- β Receptor Type 1

Transforming Growth Factor- β Receptor type 1 (TGF-βR1) is an important anticancer target involved in promoting cell proliferation, progression, and metastasis through the induction of angiogenesis and suppression of immunological responses during the late stage of malignancy. Tranilast was initiall...

Full description

Bibliographic Details
Main Authors: Nusaiba A. Babiker, Ahmed T. Negmeldin, Eman M. El-labbad
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Medical Sciences Forum
Subjects:
TGFβ-R1
Tranilast
FBDD
docking
Online Access:https://www.mdpi.com/2673-9992/14/1/75

Internet

https://www.mdpi.com/2673-9992/14/1/75

Similar Items